Insider Selling: Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Sells $23,010.00 in Stock

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) COO Tina Marriott sold 3,000 shares of the business’s stock in a transaction dated Thursday, April 25th. The stock was sold at an average price of $7.67, for a total value of $23,010.00. Following the transaction, the chief operating officer now owns 543,231 shares of the company’s stock, valued at $4,166,581.77. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website.

Tina Marriott also recently made the following trade(s):

• On Thursday, March 21st, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $10.75, for a total transaction of $86,000.00.
• On Thursday, February 22nd, Tina Marriott sold 8,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $14.89, for a total transaction of $119,120.00.

Recursion Pharmaceuticals Trading Up 6.6 %

Recursion Pharmaceuticals stock opened at $8.34 on Thursday. Recursion Pharmaceuticals, Inc. has a twelve month low of $4.54 and a twelve month high of $16.75. The company has a 50 day moving average of $10.18 and a 200-day moving average of $9.17.

Recursion Pharmaceuticals (NASDAQ:RXRX) last released its earnings results on Tuesday, February 27th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.46) by $0.06. The firm had revenue of $10.89 million during the quarter, compared to analysts’ expectations of $12.37 million. Recursion Pharmaceuticals had a negative return on equity of 72.88% and a negative net margin of 735.99%. As a group, analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.63 EPS for the current fiscal year.

Institutional Inflows and Outflows

A number of hedge funds have recently modified their holdings of RXRX. Hussman Strategic Advisors Inc. acquired a new position in Recursion Pharmaceuticals during the 1st quarter worth approximately $419,000. Capstone Investment Advisors LLC acquired a new stake in shares of Recursion Pharmaceuticals in the first quarter valued at approximately $161,000. Janney Montgomery Scott LLC bought a new stake in shares of Recursion Pharmaceuticals in the first quarter worth $310,000. Benjamin F. Edwards & Company Inc. acquired a new position in Recursion Pharmaceuticals during the first quarter worth $26,000. Finally, China Universal Asset Management Co. Ltd. grew its position in Recursion Pharmaceuticals by 81.2% in the first quarter. China Universal Asset Management Co. Ltd. now owns 43,656 shares of the company’s stock valued at $435,000 after purchasing an additional 19,565 shares in the last quarter. 89.06% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on RXRX. TD Cowen initiated coverage on shares of Recursion Pharmaceuticals in a research report on Friday, January 26th. They set a “market perform” rating on the stock. KeyCorp raised their price objective on Recursion Pharmaceuticals from $15.00 to $16.00 and gave the stock an “overweight” rating in a research note on Monday, March 4th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $17.00 target price on shares of Recursion Pharmaceuticals in a research note on Tuesday, April 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to data from MarketBeat.com, Recursion Pharmaceuticals has a consensus rating of “Hold” and a consensus price target of $12.75.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.